Multiple Myeloma

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Sagar Lonial MD, FACP, discusses unanswered questions with T-cell engagers in myeloma.

November 23, 2020 - The China National Medical Products Administration has approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in those with multiple myeloma.

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Saad Z. Usmani, MD, FACP, discusses the significance of the FDA approval of daratumumab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma who have received at least 1 previous line of therapy.

November 18, 2020 - The FDA has decided to lift the clinical hold placed on the phase 1 MELANI-01 trial, which is examining the CAR T-cell therapy UCARTCS1 as a treatment for patients with relapsed/refractory multiple myeloma.

In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

Regulatory applications have been submitted to the FDA and the European Medicines Agency for subcutaneous daratumumab for use in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

Caitlin Costello, MD, discusses treatment selection considerations in multiple myeloma.

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Sagar Lonial, MD, FACP, discusses the role of BCMA ​as a target in multiple myeloma.

Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

Andrew Kin, MD, discusses the shift in goals for frontline treatment in multiple myeloma.

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

In our exclusive interview, Saad Z. Usmani, MD, FACP, discusses the FDA approval of daratumumab, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma.

Single-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.

Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.

Derek C. Galligan, MD, discusses transplant eligibility in determining subsequent treatment for patients with multiple myeloma.

Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.

The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for select patients with relapsed/refractory multiple myeloma.

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.

Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.